The Gross Law Firm Announces Class Actions on Behalf of Shareholders of LCID, AUPH and OSCR

The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery

Lucid Group, Inc. (NASDAQ:LCID)

This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Lucid common stock between November 15, 2021, and February 28, 2022, inclusive.

A class action has commenced on behalf of certain shareholders in Lucid Group, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Lucid's business and operations. Specifically, the Company overstated its production capabilities while concealing that "extraordinary supply chain and logistics challenges" were hampering Lucid's operations. As a result of the defendants' wrongful acts and omissions, and the significant decline in the market value of Lucid's common stock, Lucid investors have suffered significant damages.

Shareholders may find more information at https://securitiesclasslaw.com/securities/lucid-group-inc-loss-submission-form/?id=27441&from=1

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Investors Affected : May 7, 2021 - February 25, 2022

A class action has commenced on behalf of certain shareholders in Aurinia Pharmaceuticals Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Aurinia was experiencing declining revenues; (ii) Aurinia's 2022 sales outlook for the Company's only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS's commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/aurinia-pharmaceuticals-inc-loss-submission-form/?id=27441&from=1

Oscar Health, Inc. (NYSE:OSCR)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Oscar Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's March 2021 initial public offering.

A class action has commenced on behalf of certain shareholders in Oscar Health, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Oscar was experiencing growing COVID-19 testing and treatment costs; (2) Oscar was experiencing growing net COVID costs; (3) Oscar would be negatively impacted by an unfavorable prior year Risk Adjustment Data Validation result relating to 2019 and 2020; (4) Oscar was on track to be negatively impacted by significant SEP membership growth; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/oscar-health-inc-loss-submission-form/?id=27441&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE : The Gross Law Firm